Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: Adjusting the bullet to its target

Expert Opinion on Biological Therapy

Volumn 13, Issue 8, 2013, Pages 1149-1160

  de Vos, Jens ^a,b   Devoogdt, Nick ^a   Lahoutte, Tony ^a,c   Muyldermans, Serge ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

biodistribution; blood brain barrier permeability; camelid single domain antibody fragment; clinical molecular imaging; cross reactivity; diagnosis; nanobody; probe; radionuclide labeling; tracer

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; NANOBODY; DIAGNOSTIC AGENT;

ANIMAL; DIAGNOSTIC USE; EVALUATION STUDY; HUMAN; MOLECULAR IMAGING; REVIEW;

ANIMALS; EVALUATION STUDIES AS TOPIC; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR IMAGING; SINGLE-DOMAIN ANTIBODIES;

EID: 84887152511     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2013.800478     Document Type: Review

References (94)

1. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007; 48 (6): 18N; 21N
2. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7 (7): 591 - 607
3. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010; 49 (7): 1364 - 76
4. Lin X, Xie J, Chen X. Protein-based tumor molecular imaging probes. Amino Acids 2011; 41 (5): 1013 - 36
5. Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. JACC Cardiovasc Imaging 2011; 4 (7): 799 - 806
6. Peterson TE, Manning HC. Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol 2009; 37 (3): 151 - 61
7. Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got? Eur Heart J 2009; 30 (21): 2566 - 74
8. Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009; 70 (2): 205 - 11
9. Wilbanks T, Peterson JA, Miller S, et al. Localization of mammary tumors in vivo with 131I-labeled Fab fragments of antibodies against mouse mammary epithelial (MME) antigens. Cancer 1981; 48 (8): 1768 - 75
10. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53 (17): 4026 - 34
11. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56 (13): 3055 - 61
12. Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44 (12): 1962 - 9
13. Orlova A, Nilsson FY, Wikman M, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006; 47 (3): 512 - 19
14. Cortez-Retamozo V, Lahoutte T, Caveliers V, et al. 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression. Curr Radiopharm 2008; 1 (1): 37 - 41
15. Tijink BM, Perk LR, Budde M, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009; 36 (8): 1235 - 44
16. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009; 69 (6): 2435 - 42
17. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70 (4): 1595 - 605
18. Hackel BJ, Kimura RH, Gambhir SS. Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology 2012; 263 (1): 179 - 88
19. Olafsen T, Sirk SJ, Olma S, et al. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol 2012; 33 (3): 669 - 77
20. Heskamp S, Laverman P, Rosik D, et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 2012; 53 (1): 146 - 53
21. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012; 72 (16): 4165 - 77
22. Delaloye B, Bischof-Delaloye A, Buchegger F, et al. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986; 77 (1): 301 - 11
23. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc. Cancer Res 1990; 50 (3 Suppl): 909s - 21s
24. Wong JY, Chu DZ, Williams LE, et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004; 10 (15): 5014 - 21
25. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-Labeled affibody molecules. J Nucl Med 2010; 51 (6): 892 - 7
26. Xavier C, Vaneycken I, D'Huyvetter M, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-Anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med 2013; Epub ahead of print
27. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012; 30 (31): 3884 - 92
28. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996; 26 (3): 690 - 6
29. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 2003; 15 (2): 187 - 95
30. Ober RJ, Martinez C, Vaccaro C, et al. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor. FcRn. J Immunol 2004; 172 (4): 2021 - 9
31. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63 (3): 136 - 51
32. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363 (6428): 446 - 8
33. Arbabi Ghahroudi M, Desmyter A, Wyns L, et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997; 414 (3): 521 - 6
34. Muyldermans S, Baral TN, Retamozzo VC, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 2009; 128 (1-3): 178 - 83
35. Nuttall SD. Overview and discovery of IgNARs and generation of VNARs. Methods Mol Biol 2012; 911: 27 - 36
36. Vaneycken I, D'Huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol 2011; 22 (6): 877 - 81
37. Devoogdt N, Xavier C, Hernot S, et al. Molecular imaging using Nanobodies: a case study. Methods Mol Biol 2012; 911: 559 - 67
38. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23 (9): 1126 - 36
39. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002; 98 (3): 456 - 62
40. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009; 10 (11): 1212 - 24
41. Vincke C, Loris R, Saerens D, et al. General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold. J Biol Chem 2009; 284 (5): 3273 - 84
42. Vaneycken I, Govaert J, Vincke C, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 2010; 51 (7): 1099 - 106
43. Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003; 332 (2): 489 - 503
44. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 17 (5): 455 - 62
45. Hansson M, Ringdahl J, Robert A, et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 1999; 4 (3-4): 237 - 52
46. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001; 276 (10): 7346 - 50
47. Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005; 20 (3): 239 - 48
48. Friedrich K, Hanauer JR, Prufer S, et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther 2013; 21 (4): 849 - 59
49. Emanuel SL, Engle LJ, Chao G, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3 (1): 38 - 48
50. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008; 49 (5): 788 - 95
51. Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008; 10 (3): 167 - 75
52. Gainkam LO, Keyaerts M, Caveliers V, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol 2011; 13 (5): 940 - 8
53. Tchouate Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011; 6 (2): 85 - 92
54. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011; 25 (7): 2433 - 46
55. D'Huyvetter M, Aerts A, Xavier C, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 2012; 7 (2): 254 - 64
56. Oliveira S, van Dongen GA, Stigter-van Walsum M, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 2012; 11 (1): 33 - 46
57. Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 2001; 276 (28): 26285 - 90
58. Rasmussen SG, Choi HJ, Fung JJ, et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011; 469 (7329): 175 - 80
59. Broisat A, Hernot S, Toczek J, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res 2012; 110 (7): 927 - 37
60. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002; 11 (3): 500 - 15
61. Dolk E, van Vliet C, Perez JM, et al. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins 2005; 59 (3): 555 - 64
62. van der Linden RH, Frenken LG, de Geus B, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999; 1431 (1): 37 - 46
63. Van de Broek B, Devoogdt N, D'Hollander A, et al. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano 2011; 5 (6): 4319 - 28
64. Xavier C, Devoogdt N, Hernot S, et al. Site-specific labeling of his-tagged Nanobodies with (9)(9)mTc: a practical guide. Methods Mol Biol 2012; 911: 485 - 90
65. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003; 9 (1): 123 - 8
66. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25 (2): 201 - 12
67. Pruszynski M, Koumarianou E, Vaidyanathan G, et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 2013; 40 (1): 52 - 9
68. Fani M, Andre JP, Maecke HR. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008; 3 (2): 67 - 77
69. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005; 95 (4): 1201 - 14
70. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32 (11): 1959 - 72
71. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. Faseb J 2002; 16 (2): 240 - 2
72. Caljon G, Caveliers V, Lahoutte T, et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br J Pharmacol 2012; 165 (7): 2341 - 53
73. Nabuurs RJ, Rutgers KS, Welling MM, et al. In vivo detection of amyloid-beta deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease. PLoS One 2012; 7 (6): e38284
74. Li T, Bourgeois JP, Celli S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J 2012; 26 (10): 3969 - 79
75. Rutgers KS, Nabuurs RJ, van den Berg SA, et al. Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. Neuroscience 2011; 190: 37 - 42
76. Jones DR, Taylor WA, Bate C, et al. A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS One 2010; 5 (3): e9804
77. Iqbal U, Albaghdadi H, Luo Y, et al. Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br J Cancer 2010; 103 (10): 1606 - 16
78. Iqbal U, Trojahn U, Albaghdadi H, et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharmacol 2010; 160 (4): 1016 - 28
79. Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 2005; 23 (41): 4926 - 34
80. Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006; 54 (6): 1856 - 66
81. Vugmeyster Y, Entrican CA, Joyce AP, et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). Bioconjug Chem 2012; 23 (7): 1452 - 62
82. De Groeve K, Deschacht N, De Koninck C, et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med 2010; 51 (5): 782 - 9
83. Put S, Schoonooghe S, Devoogdt N, et al. SPECT imaging of joint inflammation with nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med 2013;
84. Vosjan MJ, Perk LR, Roovers RC, et al. Facile labelling of an anti-epidermal growth factor receptor Nanobody with (68)Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 2011; 38 (4): 753 - 63
85. Bell A, Wang ZJ, Arbabi-Ghahroudi M, et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett 2010; 289 (1): 81 - 90
86. Vosjan MJ, Vercammen J, Kolkman JA, et al. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 2012; 11 (4): 1017 - 25
87. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7 (8): 2288 - 97
88. Hernot S, Unnikrishnan S, Du Z, et al. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release 2012; 158 (2): 346 - 53
89. Ahlgren S, Wallberg H, Tran TA, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009; 50 (5): 781 - 9
90. Willuda J, Kubetzko S, Waibel R, et al. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 2001; 276 (17): 14385 - 92
91. Tang Y, Scollard D, Chen P, et al. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005; 26 (5): 427 - 32
92. Olafsen T, Tan GJ, Cheung CW, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004; 17 (4): 315 - 23
93. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22 (6): 701 - 6
94. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50 (6): 974 - 81